Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company focused on developing best-in-class therapies for rare cardiopulmonary diseases such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company utilizes its proprietary PRINT® technology to enhance the efficacy, tolerability, and convenience of medicines. Its pipeline includes L606, an investigational sustained-release liposomal formulation of treprostinil developed in partnership with Pharmosa Biopharm.

Liquidia Corporation is a biopharmaceutical company. It is dedicated to developing best-in-class therapies for rare cardiopulmonary diseases like pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company uses its proprietary PRINT® technology to enhance the efficacy, tolerability, and convenience of medicines. Its pipeline includes L606, an investigational sustained-release liposomal formulation of treprostinil developed in partnership with Pharmosa Biopharm.

1. 1Liquidia Corporation | Corporate Websiteliquidia.com
2. 2Pipeline & Products | Liquidia Corporationliquidia.com
3. 3Liquidia Corporationwikidata.org